Inicio
Información del autor
Autor Ana María Guevara Zambrano
Comentario :
Médica Ginecóloga, Hospital Pablo Tobón Uribe
|
Documentos disponibles escritos por este autor (5)
Clasificado(s) por (Año de edición descendente) Refinar búsquedaCaracterización clínica y epidemiológica de pacientes con enfermedad de von Willebrand que consultan por sangrado uterino anormal atendidas en una institución de alto nivel de complejidad / Ana María Guevara Zambrano
Título : Caracterización clínica y epidemiológica de pacientes con enfermedad de von Willebrand que consultan por sangrado uterino anormal atendidas en una institución de alto nivel de complejidad Tipo de documento : documento electrónico Autores : Ana María Guevara Zambrano, Fecha de publicación : 2021 Títulos uniformes : Revista de Obstetricia y Ginecología de Venezuela Idioma : Español (spa) Palabras clave : Enfermedad de von Willebrand Factor de von Willebrand Sangrado uterino anormal Metrorragia Resumen : Caracterizar clínica y epidemiológicamente las pacientes con enfermedad de von Willebrand y sangrado uterino anormal. Métodos: Estudio observacional descriptivo transversal, en mujeres con diagnóstico de enfermedad de von Willebrand que consultaron en una institución de alta complejidad de la ciudad de Medellín. El análisis se llevó a cabo a través del programa SPSS V 24. Resultados: Se incluyeron 70 pacientes, 50 de estas fueron descartadas por no presentar hemorragia uterina anormal otener otros diagnósticos que podían intervenir en la caracterización como síndrome antifosfolípido. La mediana de la edad de las pacientes incluidas fue de 19,5 años (mín: 11, máx: 52), 9 pacientes (60%) planificaban, los métodos reportados fueron anticonceptivos orales combinados (26,7%), dispositivos intrauterinos (20%) y métodos quirúrgicos (13,3 %). En cuanto a la caracterización clínica realizada, se encontró que la presencia de hematomas 40% (8) y epistaxis 40% (8) fueron las manifestaciones más frecuentes. La mayoría de las pacientes, 65% (13) no había recibido tratamiento previo ala consulta para la hemorragia uterina anormal. Respecto a la evaluación de los paraclínicos se encontró: hemoglobina 13 g/dL (6,6 – 15,7), hematocrito 37,5 % (20,3 – 46,1), plaquetas 279 000 células/mm3 (106 000 – 393 000), antígenoplasmático factor de von Willebrand 68,5 UI (19,7 – 205), actividad plasmática del factor de von Willebrand 44 UI (23 – 126). Conclusión: El sangrado uterino anormal es una manifestación frecuente en mujeres con enfermedad de von Willebrandy puede llegar a presentarse en distintas etapas de la vida, pese a su diagnóstico, las mujeres no reciben manejo de estamanifestación clínica sino hasta su consulta con ginecología. Mención de responsabilidad : Lina María Martínez-Sánchez, Ana María Guevara-Zambrano, María Patricia Hormaza-Ángel, Johan Harley Muñoz-Ríos, Mabel Dahiana Roldán-Tabares, Laura Isabel Jaramillo-Jaramillo, Laura Herrera-Almanza, Juan Diego Villegas-Alzate DOI (Digital Object Identifier) : 10.51288/00810309 En línea : http://saber.ucv.ve/ojs/index.php/rev_ogv/article/view/23188 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=5853 Caracterización clínica y epidemiológica de pacientes con enfermedad de von Willebrand que consultan por sangrado uterino anormal atendidas en una institución de alto nivel de complejidad [documento electrónico] / Ana María Guevara Zambrano, . - 2021.
Obra : Revista de Obstetricia y Ginecología de Venezuela
Idioma : Español (spa)
Palabras clave : Enfermedad de von Willebrand Factor de von Willebrand Sangrado uterino anormal Metrorragia Resumen : Caracterizar clínica y epidemiológicamente las pacientes con enfermedad de von Willebrand y sangrado uterino anormal. Métodos: Estudio observacional descriptivo transversal, en mujeres con diagnóstico de enfermedad de von Willebrand que consultaron en una institución de alta complejidad de la ciudad de Medellín. El análisis se llevó a cabo a través del programa SPSS V 24. Resultados: Se incluyeron 70 pacientes, 50 de estas fueron descartadas por no presentar hemorragia uterina anormal otener otros diagnósticos que podían intervenir en la caracterización como síndrome antifosfolípido. La mediana de la edad de las pacientes incluidas fue de 19,5 años (mín: 11, máx: 52), 9 pacientes (60%) planificaban, los métodos reportados fueron anticonceptivos orales combinados (26,7%), dispositivos intrauterinos (20%) y métodos quirúrgicos (13,3 %). En cuanto a la caracterización clínica realizada, se encontró que la presencia de hematomas 40% (8) y epistaxis 40% (8) fueron las manifestaciones más frecuentes. La mayoría de las pacientes, 65% (13) no había recibido tratamiento previo ala consulta para la hemorragia uterina anormal. Respecto a la evaluación de los paraclínicos se encontró: hemoglobina 13 g/dL (6,6 – 15,7), hematocrito 37,5 % (20,3 – 46,1), plaquetas 279 000 células/mm3 (106 000 – 393 000), antígenoplasmático factor de von Willebrand 68,5 UI (19,7 – 205), actividad plasmática del factor de von Willebrand 44 UI (23 – 126). Conclusión: El sangrado uterino anormal es una manifestación frecuente en mujeres con enfermedad de von Willebrandy puede llegar a presentarse en distintas etapas de la vida, pese a su diagnóstico, las mujeres no reciben manejo de estamanifestación clínica sino hasta su consulta con ginecología. Mención de responsabilidad : Lina María Martínez-Sánchez, Ana María Guevara-Zambrano, María Patricia Hormaza-Ángel, Johan Harley Muñoz-Ríos, Mabel Dahiana Roldán-Tabares, Laura Isabel Jaramillo-Jaramillo, Laura Herrera-Almanza, Juan Diego Villegas-Alzate DOI (Digital Object Identifier) : 10.51288/00810309 En línea : http://saber.ucv.ve/ojs/index.php/rev_ogv/article/view/23188 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=5853 Reserva
Reservar este documentoEjemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD001791 AC-2021-103 Archivo digital Producción Científica Artículos científicos Disponible
Título : Maternal transfer of anti HPV 6 and 11 antibodies upon immunization with the 9-valent HPV vaccine Tipo de documento : documento electrónico Autores : Ana María Guevara Zambrano, Fecha de publicación : 2019 Títulos uniformes : Human Vaccines & Immunotherapeutics Idioma : Inglés (eng) Palabras clave : Human papillomavirus 9vHPV vaccine recurrent respiratory papillomatosis clinical trial geometric mean titers (GMTs) Resumen : Background: This exploratory analysis was conducted to characterize the level of HPV types 6/11 antibodies in peripartum maternal blood and in cord blood of infants born to women who received 9-valent HPV (9vHPV) vaccine or quadrivalent HPV (qHPV) vaccine in a pivotal efficacy study (V503-001, NCT 00543543). Methods: A total of 21 mother-infant pairs had evaluable HPV 6/11 results available for analysis. HPV6/11 antibodies were assessed using competitive Luminex immunoassay. The distribution of the ratios of infant to mother anti-HPV antibodies (i.e., infant-anti-HPV/mother- anti-HPV) was summarized. Results: All mothers and infants were seropositive to HPV 6 and HPV 11. Anti-HPV 6/11 geometric mean titers (GMTs) in peripartum maternal blood and in cord blood of infant born to study participants were highly correlated. A 100% of infants born to seropositive mothers were also seropositive. The GMT ratios of peripartum maternal blood vs. those in cord blood were HPV 6: 1.23 [0.43, 3.49] and HPV 11: 1.29 [0.54, 3.07] in the 9vHPV vaccine group and HPV 6: 1.33 [0.41, 4.29] and HPV 11: 1.19 [0.45, 3.13] in the qHPV vaccine group, respectively. Conclusions: These results indicate that antibodies induced by the 9vHPV vaccine cross the placenta, which could potentially be beneficial against HPV6/11 infection and related disease such as recurrent respiratory papillomatosis. Mención de responsabilidad : Ana Maria Guevara, Eugenio Suarez, Alejandro Victoria, Hextan Ys Ngan, Angelica Lindén Hirschberg, Edison Fedrizzi, Oliver Bautista, Christine Shields, Amita Joshi, Alain Luxembourg Referencia : Hum Vaccin Immunother. 2019;15(1):141-145. DOI (Digital Object Identifier) : 10.1080/21645515.2018.1514227 PMID : 30261146 En línea : https://www.tandfonline.com/doi/abs/10.1080/21645515.2018.1514227?journalCode=kh [...] Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=4174 Maternal transfer of anti HPV 6 and 11 antibodies upon immunization with the 9-valent HPV vaccine [documento electrónico] / Ana María Guevara Zambrano, . - 2019.
Obra : Human Vaccines & Immunotherapeutics
Idioma : Inglés (eng)
Palabras clave : Human papillomavirus 9vHPV vaccine recurrent respiratory papillomatosis clinical trial geometric mean titers (GMTs) Resumen : Background: This exploratory analysis was conducted to characterize the level of HPV types 6/11 antibodies in peripartum maternal blood and in cord blood of infants born to women who received 9-valent HPV (9vHPV) vaccine or quadrivalent HPV (qHPV) vaccine in a pivotal efficacy study (V503-001, NCT 00543543). Methods: A total of 21 mother-infant pairs had evaluable HPV 6/11 results available for analysis. HPV6/11 antibodies were assessed using competitive Luminex immunoassay. The distribution of the ratios of infant to mother anti-HPV antibodies (i.e., infant-anti-HPV/mother- anti-HPV) was summarized. Results: All mothers and infants were seropositive to HPV 6 and HPV 11. Anti-HPV 6/11 geometric mean titers (GMTs) in peripartum maternal blood and in cord blood of infant born to study participants were highly correlated. A 100% of infants born to seropositive mothers were also seropositive. The GMT ratios of peripartum maternal blood vs. those in cord blood were HPV 6: 1.23 [0.43, 3.49] and HPV 11: 1.29 [0.54, 3.07] in the 9vHPV vaccine group and HPV 6: 1.33 [0.41, 4.29] and HPV 11: 1.19 [0.45, 3.13] in the qHPV vaccine group, respectively. Conclusions: These results indicate that antibodies induced by the 9vHPV vaccine cross the placenta, which could potentially be beneficial against HPV6/11 infection and related disease such as recurrent respiratory papillomatosis. Mención de responsabilidad : Ana Maria Guevara, Eugenio Suarez, Alejandro Victoria, Hextan Ys Ngan, Angelica Lindén Hirschberg, Edison Fedrizzi, Oliver Bautista, Christine Shields, Amita Joshi, Alain Luxembourg Referencia : Hum Vaccin Immunother. 2019;15(1):141-145. DOI (Digital Object Identifier) : 10.1080/21645515.2018.1514227 PMID : 30261146 En línea : https://www.tandfonline.com/doi/abs/10.1080/21645515.2018.1514227?journalCode=kh [...] Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=4174 Reserva
Reservar este documentoEjemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD000788 AC-2018-075 Archivo digital Producción Científica Artículos científicos Disponible 
Título : Efficacy, immunogenicity, and safety of a 9-valent human papillomavirus vaccine in Latin American girls, boys, and young women Tipo de documento : documento electrónico Autores : Ana María Guevara Zambrano, Fecha de publicación : 2018 Títulos uniformes : Papillomavirus Research Idioma : Inglés (eng) Palabras clave : 9vHPV cervical cancer human papillomavirus persistent infection vaccine Resumen : Background: A 9-valent human papillomavirus (HPV6/11/16/18/31/33/45/52/58; 9vHPV) vaccine was developed to expand coverage of the previously developed quadrivalent (HPV6/11/16/18; qHPV) vaccine. Methods: Efficacy, immunogenicity, and safety outcomes were assessed in Latin American participants enrolled in 2 international studies of the 9vHPV vaccine, including a randomized, double-blinded, controlled with qHPV vaccine, efficacy, immunogenicity, and safety study in young women aged 16–26 years, and an immunogenicity and safety study in girls and boys aged 9–15 years. Participants (N=5312) received vaccination at Day 1, Month 2, and Month 6. Gynecological swabs were collected regularly in young women for cytological and HPV DNA testing. Serum was analyzed for HPV antibodies in all participants. Adverse events (AEs) were also monitored in all participants. Results: The 9vHPV vaccine prevented HPV 31-, 33-, 45-, 52-, and 58-related high-grade cervical, vulvar, and vaginal dysplasia with 92.3% efficacy (95% confidence interval 54.4, 99.6). Anti-HPV6, 11, 16, and 18 geometric mean titers at Month 7 were similar in the 9vHPV and qHPV vaccination groups. Anti-HPV antibody responses following vaccination were higher among girls and boys than in young women. Most (>99%) 9vHPV vaccine recipients seroconverted for all 9 HPV types at Month 7. Antibody responses to the 9 HPV types persisted over 5 years. The most common AEs were injection-site related, mostly of mild to moderate intensity. Conclusions: The 9vHPV vaccine is efficacious, immunogenic, and well tolerated in Latin American young women, girls, and boys. These data support 9vHPV vaccination programs in Latin America, a region with substantial cervical cancer burden. Mención de responsabilidad : Ángela María Ruiz-Sternberg, Edson D Moreira Jr, Jaime A Restrepo, Eduardo Lazcano-Ponce, Robinson Cabello, Arnaldo Silva, Rosires Andrade, Francisco Revollo, Santos Uscanga, Alejandro Victoria, Ana María Guevara, Joaquín Luna, Manuel Plata, Claudia Nossa Dominguez, Edison Fedrizzi, Eugenio Suarez, Julio C Reina, Misoo C Ellison, Erin Moeller, Michael Ritter, Christine Shields, Miguel Cashat, Gonzalo Perez, Alain Luxembourg Referencia : Papillomavirus Res. 2018 Jun;5:63-74. DOI (Digital Object Identifier) : 10.1016/j.pvr.2017.12.004 PMID : 29269325 Derechos de uso : CC BY-NC-ND En línea : https://linkinghub.elsevier.com/retrieve/pii/S2405852117300654 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=4196 Efficacy, immunogenicity, and safety of a 9-valent human papillomavirus vaccine in Latin American girls, boys, and young women [documento electrónico] / Ana María Guevara Zambrano, . - 2018.
Obra : Papillomavirus Research
Idioma : Inglés (eng)
Palabras clave : 9vHPV cervical cancer human papillomavirus persistent infection vaccine Resumen : Background: A 9-valent human papillomavirus (HPV6/11/16/18/31/33/45/52/58; 9vHPV) vaccine was developed to expand coverage of the previously developed quadrivalent (HPV6/11/16/18; qHPV) vaccine. Methods: Efficacy, immunogenicity, and safety outcomes were assessed in Latin American participants enrolled in 2 international studies of the 9vHPV vaccine, including a randomized, double-blinded, controlled with qHPV vaccine, efficacy, immunogenicity, and safety study in young women aged 16–26 years, and an immunogenicity and safety study in girls and boys aged 9–15 years. Participants (N=5312) received vaccination at Day 1, Month 2, and Month 6. Gynecological swabs were collected regularly in young women for cytological and HPV DNA testing. Serum was analyzed for HPV antibodies in all participants. Adverse events (AEs) were also monitored in all participants. Results: The 9vHPV vaccine prevented HPV 31-, 33-, 45-, 52-, and 58-related high-grade cervical, vulvar, and vaginal dysplasia with 92.3% efficacy (95% confidence interval 54.4, 99.6). Anti-HPV6, 11, 16, and 18 geometric mean titers at Month 7 were similar in the 9vHPV and qHPV vaccination groups. Anti-HPV antibody responses following vaccination were higher among girls and boys than in young women. Most (>99%) 9vHPV vaccine recipients seroconverted for all 9 HPV types at Month 7. Antibody responses to the 9 HPV types persisted over 5 years. The most common AEs were injection-site related, mostly of mild to moderate intensity. Conclusions: The 9vHPV vaccine is efficacious, immunogenic, and well tolerated in Latin American young women, girls, and boys. These data support 9vHPV vaccination programs in Latin America, a region with substantial cervical cancer burden. Mención de responsabilidad : Ángela María Ruiz-Sternberg, Edson D Moreira Jr, Jaime A Restrepo, Eduardo Lazcano-Ponce, Robinson Cabello, Arnaldo Silva, Rosires Andrade, Francisco Revollo, Santos Uscanga, Alejandro Victoria, Ana María Guevara, Joaquín Luna, Manuel Plata, Claudia Nossa Dominguez, Edison Fedrizzi, Eugenio Suarez, Julio C Reina, Misoo C Ellison, Erin Moeller, Michael Ritter, Christine Shields, Miguel Cashat, Gonzalo Perez, Alain Luxembourg Referencia : Papillomavirus Res. 2018 Jun;5:63-74. DOI (Digital Object Identifier) : 10.1016/j.pvr.2017.12.004 PMID : 29269325 Derechos de uso : CC BY-NC-ND En línea : https://linkinghub.elsevier.com/retrieve/pii/S2405852117300654 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=4196 Reserva
Reservar este documentoEjemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD000810 AC-2018-097 Archivo digital Producción Científica Artículos científicos Disponible Documentos electrónicos
2018-097.pdfAdobe Acrobat PDF
Título : Antibody persistence and evidence of immune memory at 5 years following administration of the 9-valent HPV vaccine Tipo de documento : documento electrónico Autores : Ana María Guevara Zambrano, Fecha de publicación : 2017 Títulos uniformes : Vaccine Idioma : Inglés (eng) Palabras clave : 9vHPV vaccine Clinical trial Human papillomavirus Immune memory Immunogenicity Resumen : Background: The 9-valent HPV (9vHPV) vaccine was developed to prevent infection and disease related to 9 HPV types (HPV6/11/16/18/31/33/45/52/58) which cause approximately 90% of cervical cancers, HPV-related vulvar, vaginal and anal cancers, and genital warts worldwide. In a pivotal efficacy study, the 9vHPV vaccine prevented infection and disease due to the 9 vaccine types. Duration of protection remains to be determined. Vaccines that induce long-term protection are generally characterized by the generation of immune memory. The purpose of this report is to assess the persistence of HPV antibody response and existence of immune memory at 5 years post-vaccination. Methods:A subset of subjects (N = 150) who received 3 doses of 9vHPV vaccine at day 1, month 2 and month 6 in the pivotal efficacy study continued in a study extension and received a fourth dose of 9vHPV vaccine at month 60. Serum HPV antibody levels were measured pre-dose 4 and at 7 and 28 days post-dose 4 by competitive Luminex immunoassay. Adverse events were assessed using a vaccination report card. Results: HPV antibodies induced following the 3-dose series of 9vHPV vaccine in the base study persisted through month 60 with seropositivity rates ranging from 77.5% to 100%. Geometric mean titers at 1 week and 1 month post-dose 4 were 1.25–4.10 and 1.65–4.88-fold higher, respectively, than levels observed 1 month following the completion of the three-dose primary series. Seropositivity rates were >99% and 100% at 1 week and 1 month post-dose 4, respectively. The fourth dose of 9vHPV vaccine was generally well tolerated. Conclusions: A three-dose regimen of the 9vHPV vaccine induced persistent HPV antibody response through 5 years post-vaccination. Administration of a fourth dose resulted in a strong anamnestic response to all 9 vaccine types. These findings suggest that the efficacy of the 9vHPV vaccine will be long lasting Mención de responsabilidad : Ana Guevara, Robinson Cabello, Linn Woelber, Edson Duarte Moreira Jr, Elmar Joura, Olaf Reich, Christine Shields, Misoo C Ellison, Amita Joshi, Alain Luxembourg Referencia : Vaccine. 2017 Sep 5;35(37):5050-5057. DOI (Digital Object Identifier) : 10.1016/j.vaccine.2017.07.017 PMID : 28789851 En línea : https://linkinghub.elsevier.com/retrieve/pii/S0264410X17309131 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=4034 Antibody persistence and evidence of immune memory at 5 years following administration of the 9-valent HPV vaccine [documento electrónico] / Ana María Guevara Zambrano, . - 2017.
Obra : Vaccine
Idioma : Inglés (eng)
Palabras clave : 9vHPV vaccine Clinical trial Human papillomavirus Immune memory Immunogenicity Resumen : Background: The 9-valent HPV (9vHPV) vaccine was developed to prevent infection and disease related to 9 HPV types (HPV6/11/16/18/31/33/45/52/58) which cause approximately 90% of cervical cancers, HPV-related vulvar, vaginal and anal cancers, and genital warts worldwide. In a pivotal efficacy study, the 9vHPV vaccine prevented infection and disease due to the 9 vaccine types. Duration of protection remains to be determined. Vaccines that induce long-term protection are generally characterized by the generation of immune memory. The purpose of this report is to assess the persistence of HPV antibody response and existence of immune memory at 5 years post-vaccination. Methods:A subset of subjects (N = 150) who received 3 doses of 9vHPV vaccine at day 1, month 2 and month 6 in the pivotal efficacy study continued in a study extension and received a fourth dose of 9vHPV vaccine at month 60. Serum HPV antibody levels were measured pre-dose 4 and at 7 and 28 days post-dose 4 by competitive Luminex immunoassay. Adverse events were assessed using a vaccination report card. Results: HPV antibodies induced following the 3-dose series of 9vHPV vaccine in the base study persisted through month 60 with seropositivity rates ranging from 77.5% to 100%. Geometric mean titers at 1 week and 1 month post-dose 4 were 1.25–4.10 and 1.65–4.88-fold higher, respectively, than levels observed 1 month following the completion of the three-dose primary series. Seropositivity rates were >99% and 100% at 1 week and 1 month post-dose 4, respectively. The fourth dose of 9vHPV vaccine was generally well tolerated. Conclusions: A three-dose regimen of the 9vHPV vaccine induced persistent HPV antibody response through 5 years post-vaccination. Administration of a fourth dose resulted in a strong anamnestic response to all 9 vaccine types. These findings suggest that the efficacy of the 9vHPV vaccine will be long lasting Mención de responsabilidad : Ana Guevara, Robinson Cabello, Linn Woelber, Edson Duarte Moreira Jr, Elmar Joura, Olaf Reich, Christine Shields, Misoo C Ellison, Amita Joshi, Alain Luxembourg Referencia : Vaccine. 2017 Sep 5;35(37):5050-5057. DOI (Digital Object Identifier) : 10.1016/j.vaccine.2017.07.017 PMID : 28789851 En línea : https://linkinghub.elsevier.com/retrieve/pii/S0264410X17309131 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=4034 Reserva
Reservar este documentoEjemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD000630 AC-2017-019 Archivo digital Producción Científica Artículos científicos Disponible
Título : Immunogenicity and safety of the 9-valent HPV vaccine in men Tipo de documento : documento electrónico Autores : Ana María Guevara Zambrano, Fecha de publicación : 2015 Títulos uniformes : Vaccine Idioma : Inglés (eng) Palabras clave : HPV vaccine men papillomavirus cancer Resumen : Objectives: This study was designed to evaluate the immunogenicity and tolerability of a prophylactic 9-valent HPV (types 6/11/16/18/31/33/45/52/58) VLP (9vHPV) vaccine in young men 16–26 years of age in comparison to young women 16–26 years of age (the population that was used to establish 9vHPV vaccine efficacy). Safety and immunogenicity data from this study will be used to bridge 9vHPV vaccine efficacy findings in 16–26 year old women to 16–26 year old men. Methods: This study enrolled 1106 heterosexual men (HM) and 1101 women who had not yet received HPV vaccination. In addition, 313 men having sex with men (MSM) were enrolled and were evaluated separately for immunogenicity because previous results showed that antibody responses to quadrivalent HPV (types 6/11/16/18) VLP (qHPV) vaccine were lower in MSM than in HM. All subjects were administered a 3-dose regimen (Day 1, Month 2, Month 6) of 9vHPV vaccine. Serum samples were collected for anti-HPV assays. Safety information was collected for ∼12 months. Results: The geometric mean titers (GMTs) for HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58 for HM were non-inferior to those of women at Month 7. For all vaccine HPV types, Month 7 GMTs were numerically lower in MSM than in HM. Over 99.5% of subjects were seropositive at Month 7 for each vaccine HPV type. Administration of 9vHPV vaccine to both 16–26 year old men and women was generally well tolerated. Conclusions: These results support bridging the efficacy findings with 9vHPV vaccine in young women 16–26 years of age to men 16–26 years of age. Mención de responsabilidad : X Castellsagué, A R Giuliano, S Goldstone, A Guevara, O Mogensen, J M Palefsky, T Group, C Shields, K Liu, R Maansson, A Luxembourg, S S Kaplan Referencia : Vaccine. 2015 Nov 27;33(48):6892-901. DOI (Digital Object Identifier) : 10.1016/j.vaccine.2015.06.088 PMID : 26144901 En línea : https://linkinghub.elsevier.com/retrieve/pii/S0264-410X(15)00903-2 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=3891 Immunogenicity and safety of the 9-valent HPV vaccine in men [documento electrónico] / Ana María Guevara Zambrano, . - 2015.
Obra : Vaccine
Idioma : Inglés (eng)
Palabras clave : HPV vaccine men papillomavirus cancer Resumen : Objectives: This study was designed to evaluate the immunogenicity and tolerability of a prophylactic 9-valent HPV (types 6/11/16/18/31/33/45/52/58) VLP (9vHPV) vaccine in young men 16–26 years of age in comparison to young women 16–26 years of age (the population that was used to establish 9vHPV vaccine efficacy). Safety and immunogenicity data from this study will be used to bridge 9vHPV vaccine efficacy findings in 16–26 year old women to 16–26 year old men. Methods: This study enrolled 1106 heterosexual men (HM) and 1101 women who had not yet received HPV vaccination. In addition, 313 men having sex with men (MSM) were enrolled and were evaluated separately for immunogenicity because previous results showed that antibody responses to quadrivalent HPV (types 6/11/16/18) VLP (qHPV) vaccine were lower in MSM than in HM. All subjects were administered a 3-dose regimen (Day 1, Month 2, Month 6) of 9vHPV vaccine. Serum samples were collected for anti-HPV assays. Safety information was collected for ∼12 months. Results: The geometric mean titers (GMTs) for HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58 for HM were non-inferior to those of women at Month 7. For all vaccine HPV types, Month 7 GMTs were numerically lower in MSM than in HM. Over 99.5% of subjects were seropositive at Month 7 for each vaccine HPV type. Administration of 9vHPV vaccine to both 16–26 year old men and women was generally well tolerated. Conclusions: These results support bridging the efficacy findings with 9vHPV vaccine in young women 16–26 years of age to men 16–26 years of age. Mención de responsabilidad : X Castellsagué, A R Giuliano, S Goldstone, A Guevara, O Mogensen, J M Palefsky, T Group, C Shields, K Liu, R Maansson, A Luxembourg, S S Kaplan Referencia : Vaccine. 2015 Nov 27;33(48):6892-901. DOI (Digital Object Identifier) : 10.1016/j.vaccine.2015.06.088 PMID : 26144901 En línea : https://linkinghub.elsevier.com/retrieve/pii/S0264-410X(15)00903-2 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=3891 Reserva
Reservar este documentoEjemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD000471 AC-2015-024 Archivo digital Producción Científica Artículos científicos Disponible
